Hodgkin's lymphoma

BMS’ Opdivo Bests Pfizer’s Adcetris in Late-Stage Hodgkin’s Lymphoma Study
BioSpace
Thu, 10/17/24 - 09:34 am
Bristol Myers Squibb
Opdivo
Pfizer
Adcetris
clinical trials
Hodgkin's lymphoma
Takeda and Pfizer report positive Phase III HD21 trial of ADCETRIS
Clinical Trials Arena
Mon, 06/3/24 - 10:31 pm
Takeda
Pfizer
Adcetris
clinical trials
Hodgkin's lymphoma
Tessa Therapeutics’ ‘Off-the-Shelf’ CAR-T Therapy Shows Promising Results in Early-Stage Study of Hodgkin Lymphoma
BioSpace
Fri, 06/16/23 - 09:46 am
Tessa Therapeutics
CAR-T
Hodgkin's lymphoma
TT11X
Seagen Touts Adcetris Early-Stage Lymphoma Data with 93% Complete Remission
BioSpace
Tue, 06/13/23 - 11:29 am
Seagen
Adcetris
Hodgkin's lymphoma
clinical trials
ASCO: Seagen's top-selling drug under threat as Bristol Myers' Opdivo beats Adcetris in lymphoma
Fierce Pharma
Sun, 06/4/23 - 04:31 pm
ASCO 2023 - Seagen
Bristol Myers Squibb
Adcetris
Opdivo
antibody-drug conjugate
Hodgkin's lymphoma
Seagen rolls out data for Adcetris combination to treat Hodgkin lymphoma
Endpoints
Mon, 12/12/22 - 10:39 pm
Seagen
Adcetris
ASH 2022
Hodgkin's lymphoma
Seagen's highest selling drug snags a label expansion for pediatric cancer patients
Endpoints
Sun, 11/13/22 - 07:01 pm
Seagen
Takeda
Adcetris
Hodgkin's lymphoma
FDA
pediatric
Merck study results signal blood cancer potential for new type of immunotherapy
BioPharma Dive
Thu, 05/26/22 - 10:40 pm
Merck
Bristol Myers Squibb
cancer
cancer immunotherapy
favezelimab
Hodgkin's lymphoma
FDA approves expanded indication for Merck’s KEYTRUDA in adult patients with relapsed or refractory cHL
Pharmaceutical Business Review
Fri, 10/16/20 - 11:05 am
Merck
FDA
Keytruda
Hodgkin's lymphoma
FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals
Endpoints
Mon, 07/6/20 - 11:01 am
ADC Therapeutics
IPOs
FDA
Cami
Hodgkin's lymphoma
Seattle Genetics Hits $30 Million Milestone With European Approval of Adcetris in Frontline Hodgkin Lymphoma
CP Wire
Mon, 02/11/19 - 10:20 am
Seattle Genetics
Adcetris
Takeda Pharmaceuticals
Hodgkin's lymphoma
Seattle Genetics Hits $30 Million Milestone With European Approval of Adcetris in Frontline Hodgkin Lymphoma
Mon, 02/11/19 - 10:20 am
Seattle Genetics
Adcetris
Takeda Pharmaceuticals
Hodgkin's lymphoma
Number 7? Celgene partner BeiGene joins the crowd with stellar PD-1/L1 data from a pivotal test
Endpoints
Mon, 07/23/18 - 09:45 am
Celgene
BeiGene
tiselizumab
Hodgkin's lymphoma
Seattle Genetics Gains Another FDA Approval
BioSpace
Thu, 03/22/18 - 09:00 am
Seattle Genetics
FDA
Adcetris
Hodgkin's lymphoma
ASH: Seattle Genetics CEO sees a big new Adcetris market, but one analyst has some doubts
Fierce Pharma
Mon, 12/11/17 - 11:35 am
ASH17
Seattle Genetics
Adcetris
Hodgkin's lymphoma
ASH17: Seattle Genetics sees market opportunity in cancer combo success
BioPharma Dive
Sun, 12/10/17 - 09:59 am
ASH17
Seattle Genetics
Adcetris
Hodgkin's lymphoma
Seattle Genetics Drug Scratches Out Win In Hodgkin Lymphoma
Forbes
Mon, 06/26/17 - 10:23 am
Seattle Genetics
Takeda
Hodgkin's lymphoma
Adcetris
Bristol-Myers and Seattle Genetics move a promising flagship combo into PhIII
Endpoints
Fri, 06/2/17 - 11:16 am
Bristol-Myers
Seattle Genetics
Opdivo
Adcetris
Hodgkin's lymphoma
Merck's Keytruda Gets CHMP Nod for Lymphoma
Investopedia
Sat, 03/25/17 - 12:12 pm
Merck
Keytruda
CHMP
Hodgkin's lymphoma
FDA OKs Merck’s Keytruda for Hodgkin lymphoma, a first in blood cancer
Endpoints
Wed, 03/15/17 - 11:24 am
Merck
FDA
Keytruda
Hodgkin's lymphoma

Pages